{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:43:27Z","timestamp":1792579407266,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00702-026-03210-3","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:52:09Z","timestamp":1781790729000},"page":"2577-2587","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy and safety of botulinum neurotoxin type A in blepharospasm and hemifacial spasm: a systematic review and Bayesian network meta-analysis"],"prefix":"10.1007","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5237-5242","authenticated-orcid":false,"given":"Zs\u00f3fia","family":"K\u00fchn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rab\u00e1n","family":"Scheibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schnider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"3210_CR1","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/mds.25475","volume":"28","author":"A Albanese","year":"2013","unstructured":"Albanese A et al (2013) Phenomenology and classification of dystonia: A consensus update. Mov Disord 28:863\u2013873. https:\/\/doi.org\/10.1002\/mds.25475","journal-title":"Mov Disord"},{"key":"3210_CR2","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/phar.1196","volume":"33","author":"JJ Chen","year":"2013","unstructured":"Chen JJ, Dashtipour K (2013) Abo-, Inco-, Ona-, and Rima-Botulinum Toxins in Clinical Therapy: A Primer. Pharmacotherapy 33:304\u2013318. https:\/\/doi.org\/10.1002\/phar.1196","journal-title":"Pharmacotherapy"},{"key":"3210_CR3","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0272989X12458","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Sutton AJ, Ades AE, Welton NJ (2013) Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making 33:607\u2013617. https:\/\/doi.org\/10.1177\/0272989X12458","journal-title":"Med Decis Making"},{"key":"3210_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004900.pub3","author":"GS Duarte","year":"2020","unstructured":"Duarte GS et al (2020) Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD004900.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"3210_CR5","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1136\/jnnp.51.6.767","volume":"51","author":"F Grandas","year":"1988","unstructured":"Grandas F, Elston J, Quinn JN, Marsden CD (1988) Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry 51:767\u2013772. https:\/\/doi.org\/10.1136\/jnnp.51.6.767","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3210_CR6","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1007\/s00415-016-8050-2","volume":"263","author":"Y Han","year":"2016","unstructured":"Han Y, Stevens AL, Dashtipour K, Hauser RA, Mari Z (2016) A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia. J Neurol 263:772\u2013780. https:\/\/doi.org\/10.1007\/s00415-016-8050-2","journal-title":"J Neurol"},{"key":"3210_CR7","unstructured":"Higgins JP (2024) Chapter 6: Choosing effect measures and computing estimates of effect (chapter last updated August 2023). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane"},{"key":"3210_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1468-1331.2009.02880.x","volume":"16","author":"J Jankovic","year":"2009","unstructured":"Jankovic J (2009) Clinical efficacy and tolerability of Xeomin\u00ae in the treatment of blepharospasm. Eur J Neurol 16:14\u201318. https:\/\/doi.org\/10.1111\/j.1468-1331.2009.02880.x","journal-title":"Eur J Neurol"},{"key":"3210_CR9","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/mds.23658","volume":"26","author":"J Jankovic","year":"2011","unstructured":"Jankovic J, Comella C, Hanschmann A, Grafe S (2011) Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-A randomized trial. Mov Disord 26:1521\u20131528. https:\/\/doi.org\/10.1002\/mds.23658","journal-title":"Mov Disord"},{"key":"3210_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/toxins17040173","volume":"17","author":"S Kongsaengdao","year":"2025","unstructured":"Kongsaengdao S, Arayawichanont A, Samintharapanya K, Rojanapitayakorn P, Maneeton B, Maneeton N (2025) A 12-week prospective, double-blind, multicenter, randomized study comparing 100 units of abobotulinum toxin type A (Dysport\u00ae) and 33.33 units of neubotulinum toxin type A (Neuronox\u00ae) for the treatment of hemifacial spasm. Toxins 17:173. https:\/\/doi.org\/10.3390\/toxins17040173","journal-title":"Toxins"},{"key":"3210_CR11","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.neulet.2016.06.001","volume":"627","author":"A Kutschenko","year":"2016","unstructured":"Kutschenko A, Manig A, Reinert MC, M\u00f6nnich A, Liebetanz D (2016) In-vivo comparison of the neurotoxic potencies of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA. Neurosci Lett 627:216\u2013221. https:\/\/doi.org\/10.1016\/j.neulet.2016.06.001","journal-title":"Neurosci Lett"},{"key":"3210_CR12","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.4238\/2015.February.6.17","volume":"14","author":"YY Li","year":"2015","unstructured":"Li YY, Huang Y, Ding Q, Gu ZH, Pan XL (2015) Evaluation of concentrations of botulinum toxin A for the treatment of hemifacial spasm: a randomized double-blind crossover trial. Genet Mol Res 14:1136\u20131144. https:\/\/doi.org\/10.4238\/2015.February.6.17","journal-title":"Genet Mol Res"},{"key":"3210_CR13","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/mds.20468","volume":"20","author":"A Marchetti","year":"2005","unstructured":"Marchetti A et al (2005) Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: The REAL DOSE study. Mov Disord 20:937\u2013944. https:\/\/doi.org\/10.1002\/mds.20468","journal-title":"Mov Disord"},{"key":"3210_CR14","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.6084\/m9.figshare.12573659","volume":"37","author":"DD Mitsikostas","year":"2020","unstructured":"Mitsikostas DD, Dekundy A, Sternberg K, Althaus M, Pagan F (2020) IncobotulinumtoxinA for the treatment of blepharospasm in toxin-na\u00efve subjects: a multi-center, double-blind, randomized, placebo-controlled trial. Adv Ther 37:4249\u20134265. https:\/\/doi.org\/10.6084\/m9.figshare.12573659","journal-title":"Adv Ther"},{"key":"3210_CR15","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1080\/03007995.2021.1965975","volume":"37","author":"DD Mitsikostas","year":"2021","unstructured":"Mitsikostas DD et al (2021) Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-na\u00efve subjects. Curr Med Res Opin 37:1761\u20131768. https:\/\/doi.org\/10.1080\/03007995.2021.1965975","journal-title":"Curr Med Res Opin"},{"key":"3210_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PMED.1003082","author":"A Nikolakopoulou","year":"2020","unstructured":"Nikolakopoulou A et al (2020) Cinema: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med. https:\/\/doi.org\/10.1371\/JOURNAL.PMED.1003082","journal-title":"PLoS Med"},{"key":"3210_CR17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/BF00941758","volume":"235","author":"Z N\u00fc\u00dfgens","year":"1997","unstructured":"N\u00fc\u00dfgens Z, Roggenk\u00e4mper P (1997) Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophtalmol 235:197\u2013199. https:\/\/doi.org\/10.1007\/BF00941758","journal-title":"Graefes Arch Clin Exp Ophtalmol"},{"key":"3210_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"3210_CR19","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1098\/rstb.1999.0377","volume":"354","author":"R Pellizzari","year":"1999","unstructured":"Pellizzari R, Rossetto O, Schiavo G, Montecucco C (1999) Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philos Trans R Soc Lond B Biol Sci 354:259\u2013269. https:\/\/doi.org\/10.1098\/rstb.1999.0377","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"3210_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/WNF.0b013e3181c46f61","volume":"33","author":"EMAB Quagliato","year":"2010","unstructured":"Quagliato EMAB, Carelli EF, Viana MA (2010) Prospective, randomized, double-blind study, comparing botulinum toxins type a botox and prosigne for blepharospasm and hemifacial spasm treatment. Clin Neuropharmacol 33:27\u201331. https:\/\/doi.org\/10.1097\/WNF.0b013e3181c46f61","journal-title":"Clin Neuropharmacol"},{"key":"3210_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/01.WNF.0000236771.77021.3C","volume":"30","author":"CRM Rieder","year":"2007","unstructured":"Rieder CRM et al (2007) A double-blind, randomized, crossover study of Prosigne versus Botox in patients with blepharospasm and hemifacial spasm. Clin Neuropharmacol 30:39\u201342. https:\/\/doi.org\/10.1097\/01.WNF.0000236771.77021.3C","journal-title":"Clin Neuropharmacol"},{"key":"3210_CR22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","volume":"113","author":"P Roggenk\u00e4mper","year":"2006","unstructured":"Roggenk\u00e4mper P, Jost WH, Bihari K, Comes G, Grafe S (2006) Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 113:303\u2013312. https:\/\/doi.org\/10.1007\/s00702-005-0323-3","journal-title":"J Neural Transm"},{"key":"3210_CR23","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/jrsm.1475","volume":"12","author":"C R\u00f6ver","year":"2021","unstructured":"R\u00f6ver C et al (2021) On weakly informative prior distributions for the heterogeneity parameter in Bayesian random-effects meta-analysis. Res Synth Methods 12:448\u2013474. https:\/\/doi.org\/10.1002\/jrsm.1475","journal-title":"Res Synth Methods"},{"key":"3210_CR24","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/mds.870120627","volume":"12","author":"C Sampaio","year":"1997","unstructured":"Sampaio C et al (1997) DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-dysport and botox-assuming a ratio of 4:l. Mov Disord 12:1013\u20131018. https:\/\/doi.org\/10.1002\/mds.870120627","journal-title":"Mov Disord"},{"key":"3210_CR25","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","volume":"70","author":"DM Simpson","year":"2008","unstructured":"Simpson DM et al (2008) Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology 70:1699\u20131706. https:\/\/doi.org\/10.1212\/01.wnl.0000311389.26145.95","journal-title":"Neurology"},{"key":"3210_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC et al (2019) RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"3210_CR27","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.parkreldis.2007.11.003","volume":"14","author":"D Truong","year":"2008","unstructured":"Truong D, Comella C, Fernandez HH, Ondo WG (2008) Efficacy and safety of purified botulinum toxin type A (Dysport\u00ae) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord 14:407\u2013414. https:\/\/doi.org\/10.1016\/j.parkreldis.2007.11.003","journal-title":"Parkinsonism Relat Disord"},{"key":"3210_CR28","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/sim.6381","volume":"34","author":"RM Turner","year":"2015","unstructured":"Turner RM, Jackson D, Wei Y, Thompson SG, Higgins JPT (2015) Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-analysis. Stat Med 34:984\u2013998. https:\/\/doi.org\/10.1002\/sim.6381","journal-title":"Stat Med"},{"key":"3210_CR29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00702-010-0529-x","volume":"118","author":"B Wabbels","year":"2011","unstructured":"Wabbels B, Reichel G, Fulford-Smith A, Wright N, Roggenk\u00e4mper P (2011) Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm 118:233\u2013239. https:\/\/doi.org\/10.1007\/s00702-010-0529-x","journal-title":"J Neural Transm"},{"key":"3210_CR30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/01658107.2017.1409770","volume":"42","author":"M Wakakura","year":"2018","unstructured":"Wakakura M, Yamagami A, Iwasa M (2018) Blepharospasm in Japan: A Clinical Observational Study From a Large Referral Hospital in Tokyo. Neuro-Ophthalmology 42:275\u2013283. https:\/\/doi.org\/10.1080\/01658107.2017.1409770","journal-title":"Neuro-Ophthalmology"},{"key":"3210_CR31","first-page":"31","volume":"7","author":"TJ Walker","year":"2014","unstructured":"Walker TJ, Dayan SH (2014) Comparison and overview of currently available neurotoxins. J Clin Aesthet Dermatol 7:31\u201339","journal-title":"J Clin Aesthet Dermatol"},{"key":"3210_CR32","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1002\/(SICI)1097-4598(199812)21:12<1740::AID-MUS17>3.0.CO;2-V","volume":"21","author":"A Wang","year":"1988","unstructured":"Wang A, Jankovic J (1988) Hemifacial spasm: clinical findings and treatment. Muscle Nerve 21:1740\u20131747. https:\/\/doi.org\/10.1002\/(SICI)1097-4598(199812)21:12%3c1740::AID-MUS17%3e3.0.CO;2-V","journal-title":"Muscle Nerve"},{"key":"3210_CR33","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3341\/kjo.2009.23.3.137","volume":"23","author":"JS Yoon","year":"2009","unstructured":"Yoon JS, Kim JC, Lee SY (2009) Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm. Korean J Ophthalmol 23:137\u2013141. https:\/\/doi.org\/10.3341\/kjo.2009.23.3.137","journal-title":"Korean J Ophthalmol"},{"key":"3210_CR34","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1590\/s0004-27492008000600027","volume":"71","author":"RMB Zagui","year":"2008","unstructured":"Zagui RMB, Matayoshi S, Moura FC (2008) Efeitos adversos associados \u00e0 aplica\u00e7\u00e3o de toxina botul\u00ednica na face: revis\u00e3o sistem\u00e1tica com meta-an\u00e1lise. Arq Bras Oftalmol 71:894\u2013901. https:\/\/doi.org\/10.1590\/s0004-27492008000600027","journal-title":"Arq Bras Oftalmol"},{"key":"3210_CR35","first-page":"1587","volume":"16","author":"SZ Zhao","year":"2016","unstructured":"Zhao SZ (2016) Clinical efficacy of two concentrations of diluted botulinum toxin A for blepharospasm. International Eye Science 16:1587\u20131589","journal-title":"International Eye Science"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03210-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-026-03210-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03210-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:19:17Z","timestamp":1792577957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-026-03210-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3210"],"URL":"https:\/\/doi.org\/10.1007\/s00702-026-03210-3","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"24 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}